CAR-T cells targeting CD19 have achieved complete remission rates of 40-54%, 67%, and 69-74% in clinical trials for R/R aggressive B-cell lymphoma, mantle cell lymphoma, and inert B-cell lymphoma, respectively (3–6). Here, CD19 is linked to B-cell non-Hodgkin lymphoma.